Mechanisms underlying emergence and progression of gastric intestinal metaplasia

Active Grant Awarded

Award ID
R01CA304170
Recipient
Awarding agency
Obligated
$633,232

Award facts

Assistance listing
93.396 Cancer Biology Research
Completion date 3% complete
Place of performance
Houston, TX 77030, USA

Award details come from USAspending.gov.

About this award

The National Cancer Institute, within the National Institutes of Health and the Department of Health and Human Services, awarded Pennsylvania State University, doing business as Penn State Milton S. Hershey Medical Center, a $633,232 grant on September 17, 2026, under Assistance Listing 93.396, Cancer Biology Research. The program provides fundamental information on the cause and nature of cancer to support better methods of prevention, detection, diagnosis, and treatment of neoplastic diseases.

The award funds Grant R01CA304170, "Mechanisms Underlying Emergence and Progression of Gastric Intestinal Metaplasia." The recipient will generate mechanistic leads using a new mouse model in which deletion of the transcription factor ESRRG (ERRA) in parietal cell precursors reroutes cells to metaplastic mucous cell formation and, with age, to spontaneous pyloric metaplasia with intestinal metaplasia. Those leads will then be tested in human organoid and tissue experiments to establish human relevance. The project also tests a hypothesized regulatory circuit among SIRT1, ERRA, NR0B2 (SHP), and NR1H4 (FXR), in which bile species activate NR1H4 and NR0B2 to promote intestinal metaplasia and oppose ERRA.

The period of performance runs from the September 17, 2026 award date to August 31, 2031. Place of performance is Houston, Texas 77030. Dollars obligated total $633,232.

Description

Abstract
Gastric and esophageal adenocarcinomas frequently develop from intestinal metaplasia (IM), characterized by conversion of gastric-type glandular epithelium into intestinalized epithelium. In the stomach, IM often arises within pyloric metaplasia, featuring loss of acid-secreting parietal cells (PCS) and reprogramming of digestiveenzyme- secreting chief cells into mucinous spasmolytic polypeptide expressing metaplasia (SPEM). Which cells originate IM and how IM progresses remain difficult to investigate because they require tracking defined epithelial lineages from normal differentiation through spontaneous metaplasia within intact tissue. Our research has identified the transcription factor esrrg (ERRÃ) as necessary and sufficient for differentiation of PCS from stem cells. Deletion of esrrg in PC precursors (pre-PCS) in mice causes pre-PCS to reroute to metaplastic mucous cell formation and, as the mice become older, into spontaneous pyloric metaplasia with IM, a phenotype recapitulating human lesions. This new model uniquely enables US to determine how lineage-specific ERRÃ loss alters cell fate and drives IM over time in an intact tissue. IT is difficult to follow these processes longitudinally (IE, over time) in tissues from human patients, and human organoids alone cannot model IM because they lack the other components of intact tissue: immune and stroma cells, microbes, gastric contents (like bile and acid). Thus, here we propose to generate mechanistic leads with our new animal model and follow those up with human organoid/tissue experiments to establish human relevance in a way no single approach could. We have examined known interactions among ERRÃ and its CO-factors and hypothesize that SIRT1, ERRÃ, NR0B2 (SHP), and NR1H4 (FXR; the bile acid nuclear receptor) form a regulatory circuit: bile species activate NR1H4 and NR0B2 to promote IM and oppose ERRÃ and gastric differentiation. SIRT1 and ERRÃ support the gastric phenotype. Preliminary studies in human tissues and organoids corroborate our mouse studies indicating an ERRÃ-centered signaling circuit that maintains PC differentiation and prevents IM. Our aims are to: 1) understand in mice and human cells the molecular actions of SIRT1, ERRÃ, NR0B2, and NR1H4 to promote gastric differentiation versus IM and test ERRÃ's ability to block IM in human gastric organoids. 2) determine how ERRÃ loss in pre-PCS contributes to IM in our mouse model. Using ATP4B-CRE; esrrgä/Ä mice, we will define the cellular and molecular evolution of spontaneous IM, including lineage and single-cell analyses (e.g., scrnaseq) that require intact tissue. 3) assess if targeting ERRÃ/NR1H4 influences IM or tumorigenesis and identify new IM pathways and potential drug targets. We will test effects of manipulating ERRÃ/NR1H4 on IM progression and cancer potential in vivo and use high-resolution spatial transcriptomics of mouse and human tissues to identify drivers of IM. By integrating lineage-specific, longitudinal studies in an intact mammalian tissue with mechanistic experiments in human organoids and validation in human disease tissues, we will define mechanisms underlying IM development and identify potential targets for preventing progression to cancer.

Quick answers

Who received award R01CA304170?

R01CA304170 was awarded to Pennsylvania State University by National Cancer Institute (National Institutes of Health) on September 17, 2026.

How much is award R01CA304170 worth?

$633,232 has been obligated on R01CA304170.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award